Press Releases

TULSA, OK and VANCOUVER, BC / ACCESSWIRE / June 17, 2024 / Hydrogen Technologies ("HT"), developer of the patented, pioneering DCC™ hydrogen-fueled, zero-emission boiler, will be exhibiting and presenting at IDEA 2024, which will take place June 17-20 at the Renaissance Orlando at SeaWorld. Hydrogen Technologies - IDEA 2024 Exhibition Information

• HT will be exhibiting in the trade show at Booth #45

Hydrogen Technologies - IDEA 2024 Presentation Information

• Wednesday, June... (continue reading...)

CARSON CITY, NV - (NewMediaWire) - June 17, 2024 - LeapCharger Corporation (OTC: LCCN) ("LeapCharger or the "Company"), an electric vehicle (EV) charging company renowned for its disruptive and innovative technology providing eco-friendly and sustainable solutions, is excited to announce the signing of a Memorandum of Understanding (the MOU) to form a strategic partnership with FullyCharged Electrical Fitting, a leading provider of electrical installation services based... (continue reading...)

TORONTO, June 17, 2024 (GLOBE NEWSWIRE) -- Consolidated Lithium Metals Inc. (TSXV: CLM | OTCQB: JORFF | FRA: Z36) (“CLM” or the “Company”) reports that the nominees listed in the Management Information Circular dated May 15, 2024, (the “Circular”) for the 2024 Annual and Special Meeting of Shareholders of the Company (the “Meeting”) were elected as directors of the Company. A total of 25.42% of all of the issued and outstanding shares of the Company were represented... (continue reading...)

NEW YORK, June 17, 2024 (GLOBE NEWSWIRE) -- Lionheart Holdings (the “Company”) announced today the pricing of its initial public offering of 20,000,000 units. The units are expected to be listed on The Nasdaq Stock Market LLC (“Nasdaq”) and begin trading tomorrow, June 18, 2024, under the ticker symbol “CUBWU.” Each unit consists of one Class A ordinary share and one-half of one redeemable warrant, each whole warrant entitling the holder thereof to purchase one Class... (continue reading...)

CAPVAXIVE (V116) is specifically designed for adults and covers serotypes responsible for approximately 84% of invasive pneumococcal disease in adults 50 years of age and older

Across four Phase 3 studies, CAPVAXIVE demonstrated robust immune responses in both vaccine-naïve and vaccine-experienced adult populations

RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the U.S. Food and Drug... (continue reading...)